WX-0593 Tablets

DRUG5 trials

Sponsors

Qilu Pharmaceutical Co., Ltd., Jinming Yu, Pingping Song

Conditions

Advanced Solid Tumor, Non-small Cell Lung CancerNon-Small Cell Lung Cancer(NSCLC)Non-small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC)

Phase 1

A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients

Qilu Pharmaceutical Co., Ltd.Advanced Solid Tumor, Non-small Cell Lung Cancer

Start: 2017-09-14End: 2020-12-31Target: 48Updated: 2018-01-04

Phase 2

A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer

Qilu Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2019-03-07End: 2021-03-31Target: 176Updated: 2020-11-24

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

RecruitingNCT05351320

Jinming YuNon-small Cell Lung Cancer (NSCLC)

Start: 2022-04-30End: 2026-05-30Target: 40Updated: 2022-04-28

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

RecruitingNCT05765877

Pingping SongNon-Small Cell Lung Cancer(NSCLC)

Start: 2023-03-01End: 2029-03-31Target: 26Updated: 2025-06-12

Phase 3

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Qilu Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2019-06-01End: 2024-12-01Updated: 2023-11-24

Related Papers

Translational Model‐Informed Dose Selection for Iruplinalkib, a Selective Oral <scp>ALK</scp>/<scp>ROS1</scp> Tyrosine Kinase Inhibitor

Clinical and Translational Science2025-07-01

Neoadjuvant and adjuvant iruplinalkib in resectable <i>ALK</i> or <i>ROS1</i> fusion-positive, non-small cell lung cancer (NSCLC): The preliminary results of the single-arm, exploratory Neo-INFINITY study.

Journal of Clinical Oncology2025-05-28

Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).

2024-01-2526 citations

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).

2023-02-2417 citations

A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report

Frontiers in Oncology2022-06-304 citations

A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in <i>ALK</i>-positive and crizotinib-resistant advanced non–small cell lung cancer.

Journal of Clinical Oncology2022-06-012 citations